• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

US FDA approves Natco’s ANDA for generic version of Vidaza

expressbpdJune 29, 2017

Tag: FDA , Natco’s ANDA  ,  Vidaza

                                                      

Natco Pharma has got the final approval for Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for the generic version of Vidaza (Azacitidine for injection, 100 mg per vial), single-dose vial.

According to a company statement, Natco and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch the product in the US market in the near future.

Vidaza by Celgene Corporation is a prescription anti-cancer chemotherapy drug that is indicated to treat, myelodysplastic syndrome (MDS).Vidaza generated total combined sales of $188 million for the 12-month period ended April 2017, based on industry sales data.

Previous:Zydus Cadila to market oxybutynin chloride tablets

Next:QS Pharma receives EMA approval for medicinal products manufacturing

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

US FDA approves Natco’s ANDA for generic version of Vidaza | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

filter integrity testing fda guidelines

filter integrity testing fda guidelines
Tobramycin base( FDA)

Tobramycin base( FDA)
Vitamine B12 (FDA)

Vitamine B12 (FDA)
Nabumetone (FDA)

Nabumetone (FDA)
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Vecuronium Bromide(FDA)

Vecuronium Bromide(FDA)
Irinotecan (FDA)

Irinotecan (FDA)
4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）

4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）
Hexafluorodianhydride(6-FDA)

Hexafluorodianhydride(6-FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service